Ipsen nets US$50m for OBI-1
Enlarge image


Ipsen nets US$50m for OBI-1

25.01.2013 - Ipsen and bankrupt Inspiration Biopharmaceuticals have inked a US$185m Asset Purchase Agreement with Baxter giving it the global rights to OBN-1.

Under the terms of the agreement, Baxter will acquire the worldwide rights to the recombinant porcine factor VIII (rpFVIII) for congenital and acquired haemophilia A, and Ipsen’s industrial facility in Milford, US. The Asset Purchase Agreement (APA) was filed on 23 January 2013, with the US Federal Bankruptcy Court in Boston (MA). The sale is a result of a joint marketing and sale process pursued by Ipsen and Inspiration shortly after Inspiration filed for protection. Ipsen has been providing Inspiration with Debtor-in-Possession financing for an amount of up to $18.3m in order to permit the sale process to proceed.

Baxter will pay $50m upfront, up to $135m in potential additional milestones as well as tiered net sales payments ranging from 12.5% to 17.5% of OBI-1 annual net sales.
The APA is subject to certain closing conditions, including Bankruptcy Court and regulatory approvals. Ipsen has agreed to extend the Debtor-in-Possession (DIB) financing to Inspiration for a period of 45 days

The sale process for IB1001, a recombinant factor IX (rFIX) for the treatment and prevention of bleeding in patients with haemophilia B is separate and in the final bidding stage. As Inspiration’s only senior secured creditor and as the owner of non-Inspiration assets that will be included in the sale of both OBI-1 and IB1001, Ipsen will receive approximately 60% of the upfront payments. Over and above these upfront amounts, Ipsen will receive 80% of all payments up to a present value of $304m and 50% of all proceeds thereafter.

On the basis of available information, the share of upfront payment to be received by Ipsen should mainly cover the total amount of DIP financing provided to Inspiration. The remaining portion of proceeds is contingent on OBI-1’s approval. As a consequence, the Group, as of 31 December 2012, may impair haemophilia related assets for a total amount of around €100m after tax.



26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • EVOCUTIS (UK)0.12 GBP33.33%
  • EPIGENOMICS (D)2.65 EUR17.26%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • SERODUS (N)2.18 NOK-18.35%
  • DEINOVE (F)5.14 EUR-17.63%


  • PLETHORA (UK)5.50 GBP76.3%
  • CELLECTIS (F)31.65 EUR41.1%


  • EPIGENOMICS (D)2.65 EUR-39.6%
  • DEINOVE (F)5.14 EUR-21.3%


  • KARO BIO (S)37.90 SEK5314.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.60 EUR260.1%


  • BIOTEST (D)15.31 EUR-81.0%
  • NEOVACS (F)0.80 EUR-76.5%

No liability assumed, Date: 27.11.2015